Research ArticleArticle
Open Access
Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease, Stephen Hall, Hector Chinoy, Alan J. Kivitz, Zailong Wang and Shephard Mpofu
The Journal of Rheumatology June 2016, jrheum.160275; DOI: https://doi.org/10.3899/jrheum.160275
Arthur Kavanaugh
From the University of California-San Diego, School of Medicine, LaJolla, California, USA; Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK; Swedish Medical Centre, and University of Washington School of Medicine, Seattle, Washington, USA; Monash University, Melbourne, Australia; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service NHS Foundation Trust, University of Manchester, UK; Altoona Center for Clinical Research, Duncansville, Pennsylvania; Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA; Novartis Pharma AG, Basel, Switzerland. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. A. Kavanaugh received research grants or consultation fees from Novartis. I.B. McInnes received research grants, consultation fees, or speaker honoraria from Novartis. P.J. Mease received research grants, consultation fees, or speaker honoraria from Novartis. H. Chinoy received consulting fees/grant support from Novartis. Z. Wang is an employee of Novartis. S. Mpofu is an employee of Novartis and owns Novartis stock. A. Kavanaugh, MD, Professor of Clinical Medicine, Director of Center for Innovative Therapy, University of California–San Diego, School of Medicine; I.B. McInnes, MD, PhD, Professor of Experimental Medicine (Immunology), Muirhead Chair of Medicine and Director of Institute (School of Medicine), Immunology, Infection and Inflammation, University of Glasgow; P.J. Mease, MD, Clinical Professor, University of Washington School of Medicine, Director of the Rheumatology Clinical Research Division of Swedish Medical Center; S. Hall, MBBS, Professor, Director-Emeritus Research, Monash University; H. Chinoy, PhD, Senior Lecturer, Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, University of Manchester; A.J. Kivitz, MD, CPI, President, Altoona Center for Clinical Research; Z. Wang, PhD, Associate Director, Biometrician, Novartis; S. Mpofu, MD, Senior Global Program Medical Director, Novartis. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy, and Immunology, School of Medicine, University of California at San Diego, 9500 Gilman Dr. MC 0943, La Jolla, California 92093-0943, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 9, 2016.
Iain B. McInnes
From the University of California-San Diego, School of Medicine, LaJolla, California, USA; Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK; Swedish Medical Centre, and University of Washington School of Medicine, Seattle, Washington, USA; Monash University, Melbourne, Australia; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service NHS Foundation Trust, University of Manchester, UK; Altoona Center for Clinical Research, Duncansville, Pennsylvania; Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA; Novartis Pharma AG, Basel, Switzerland. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. A. Kavanaugh received research grants or consultation fees from Novartis. I.B. McInnes received research grants, consultation fees, or speaker honoraria from Novartis. P.J. Mease received research grants, consultation fees, or speaker honoraria from Novartis. H. Chinoy received consulting fees/grant support from Novartis. Z. Wang is an employee of Novartis. S. Mpofu is an employee of Novartis and owns Novartis stock. A. Kavanaugh, MD, Professor of Clinical Medicine, Director of Center for Innovative Therapy, University of California–San Diego, School of Medicine; I.B. McInnes, MD, PhD, Professor of Experimental Medicine (Immunology), Muirhead Chair of Medicine and Director of Institute (School of Medicine), Immunology, Infection and Inflammation, University of Glasgow; P.J. Mease, MD, Clinical Professor, University of Washington School of Medicine, Director of the Rheumatology Clinical Research Division of Swedish Medical Center; S. Hall, MBBS, Professor, Director-Emeritus Research, Monash University; H. Chinoy, PhD, Senior Lecturer, Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, University of Manchester; A.J. Kivitz, MD, CPI, President, Altoona Center for Clinical Research; Z. Wang, PhD, Associate Director, Biometrician, Novartis; S. Mpofu, MD, Senior Global Program Medical Director, Novartis. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy, and Immunology, School of Medicine, University of California at San Diego, 9500 Gilman Dr. MC 0943, La Jolla, California 92093-0943, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 9, 2016.
Philip J. Mease
From the University of California-San Diego, School of Medicine, LaJolla, California, USA; Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK; Swedish Medical Centre, and University of Washington School of Medicine, Seattle, Washington, USA; Monash University, Melbourne, Australia; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service NHS Foundation Trust, University of Manchester, UK; Altoona Center for Clinical Research, Duncansville, Pennsylvania; Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA; Novartis Pharma AG, Basel, Switzerland. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. A. Kavanaugh received research grants or consultation fees from Novartis. I.B. McInnes received research grants, consultation fees, or speaker honoraria from Novartis. P.J. Mease received research grants, consultation fees, or speaker honoraria from Novartis. H. Chinoy received consulting fees/grant support from Novartis. Z. Wang is an employee of Novartis. S. Mpofu is an employee of Novartis and owns Novartis stock. A. Kavanaugh, MD, Professor of Clinical Medicine, Director of Center for Innovative Therapy, University of California–San Diego, School of Medicine; I.B. McInnes, MD, PhD, Professor of Experimental Medicine (Immunology), Muirhead Chair of Medicine and Director of Institute (School of Medicine), Immunology, Infection and Inflammation, University of Glasgow; P.J. Mease, MD, Clinical Professor, University of Washington School of Medicine, Director of the Rheumatology Clinical Research Division of Swedish Medical Center; S. Hall, MBBS, Professor, Director-Emeritus Research, Monash University; H. Chinoy, PhD, Senior Lecturer, Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, University of Manchester; A.J. Kivitz, MD, CPI, President, Altoona Center for Clinical Research; Z. Wang, PhD, Associate Director, Biometrician, Novartis; S. Mpofu, MD, Senior Global Program Medical Director, Novartis. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy, and Immunology, School of Medicine, University of California at San Diego, 9500 Gilman Dr. MC 0943, La Jolla, California 92093-0943, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 9, 2016.
Stephen Hall
From the University of California-San Diego, School of Medicine, LaJolla, California, USA; Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK; Swedish Medical Centre, and University of Washington School of Medicine, Seattle, Washington, USA; Monash University, Melbourne, Australia; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service NHS Foundation Trust, University of Manchester, UK; Altoona Center for Clinical Research, Duncansville, Pennsylvania; Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA; Novartis Pharma AG, Basel, Switzerland. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. A. Kavanaugh received research grants or consultation fees from Novartis. I.B. McInnes received research grants, consultation fees, or speaker honoraria from Novartis. P.J. Mease received research grants, consultation fees, or speaker honoraria from Novartis. H. Chinoy received consulting fees/grant support from Novartis. Z. Wang is an employee of Novartis. S. Mpofu is an employee of Novartis and owns Novartis stock. A. Kavanaugh, MD, Professor of Clinical Medicine, Director of Center for Innovative Therapy, University of California–San Diego, School of Medicine; I.B. McInnes, MD, PhD, Professor of Experimental Medicine (Immunology), Muirhead Chair of Medicine and Director of Institute (School of Medicine), Immunology, Infection and Inflammation, University of Glasgow; P.J. Mease, MD, Clinical Professor, University of Washington School of Medicine, Director of the Rheumatology Clinical Research Division of Swedish Medical Center; S. Hall, MBBS, Professor, Director-Emeritus Research, Monash University; H. Chinoy, PhD, Senior Lecturer, Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, University of Manchester; A.J. Kivitz, MD, CPI, President, Altoona Center for Clinical Research; Z. Wang, PhD, Associate Director, Biometrician, Novartis; S. Mpofu, MD, Senior Global Program Medical Director, Novartis. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy, and Immunology, School of Medicine, University of California at San Diego, 9500 Gilman Dr. MC 0943, La Jolla, California 92093-0943, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 9, 2016.
Hector Chinoy
From the University of California-San Diego, School of Medicine, LaJolla, California, USA; Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK; Swedish Medical Centre, and University of Washington School of Medicine, Seattle, Washington, USA; Monash University, Melbourne, Australia; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service NHS Foundation Trust, University of Manchester, UK; Altoona Center for Clinical Research, Duncansville, Pennsylvania; Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA; Novartis Pharma AG, Basel, Switzerland. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. A. Kavanaugh received research grants or consultation fees from Novartis. I.B. McInnes received research grants, consultation fees, or speaker honoraria from Novartis. P.J. Mease received research grants, consultation fees, or speaker honoraria from Novartis. H. Chinoy received consulting fees/grant support from Novartis. Z. Wang is an employee of Novartis. S. Mpofu is an employee of Novartis and owns Novartis stock. A. Kavanaugh, MD, Professor of Clinical Medicine, Director of Center for Innovative Therapy, University of California–San Diego, School of Medicine; I.B. McInnes, MD, PhD, Professor of Experimental Medicine (Immunology), Muirhead Chair of Medicine and Director of Institute (School of Medicine), Immunology, Infection and Inflammation, University of Glasgow; P.J. Mease, MD, Clinical Professor, University of Washington School of Medicine, Director of the Rheumatology Clinical Research Division of Swedish Medical Center; S. Hall, MBBS, Professor, Director-Emeritus Research, Monash University; H. Chinoy, PhD, Senior Lecturer, Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, University of Manchester; A.J. Kivitz, MD, CPI, President, Altoona Center for Clinical Research; Z. Wang, PhD, Associate Director, Biometrician, Novartis; S. Mpofu, MD, Senior Global Program Medical Director, Novartis. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy, and Immunology, School of Medicine, University of California at San Diego, 9500 Gilman Dr. MC 0943, La Jolla, California 92093-0943, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 9, 2016.
Alan J. Kivitz
From the University of California-San Diego, School of Medicine, LaJolla, California, USA; Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK; Swedish Medical Centre, and University of Washington School of Medicine, Seattle, Washington, USA; Monash University, Melbourne, Australia; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service NHS Foundation Trust, University of Manchester, UK; Altoona Center for Clinical Research, Duncansville, Pennsylvania; Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA; Novartis Pharma AG, Basel, Switzerland. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. A. Kavanaugh received research grants or consultation fees from Novartis. I.B. McInnes received research grants, consultation fees, or speaker honoraria from Novartis. P.J. Mease received research grants, consultation fees, or speaker honoraria from Novartis. H. Chinoy received consulting fees/grant support from Novartis. Z. Wang is an employee of Novartis. S. Mpofu is an employee of Novartis and owns Novartis stock. A. Kavanaugh, MD, Professor of Clinical Medicine, Director of Center for Innovative Therapy, University of California–San Diego, School of Medicine; I.B. McInnes, MD, PhD, Professor of Experimental Medicine (Immunology), Muirhead Chair of Medicine and Director of Institute (School of Medicine), Immunology, Infection and Inflammation, University of Glasgow; P.J. Mease, MD, Clinical Professor, University of Washington School of Medicine, Director of the Rheumatology Clinical Research Division of Swedish Medical Center; S. Hall, MBBS, Professor, Director-Emeritus Research, Monash University; H. Chinoy, PhD, Senior Lecturer, Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, University of Manchester; A.J. Kivitz, MD, CPI, President, Altoona Center for Clinical Research; Z. Wang, PhD, Associate Director, Biometrician, Novartis; S. Mpofu, MD, Senior Global Program Medical Director, Novartis. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy, and Immunology, School of Medicine, University of California at San Diego, 9500 Gilman Dr. MC 0943, La Jolla, California 92093-0943, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 9, 2016.
Zailong Wang
From the University of California-San Diego, School of Medicine, LaJolla, California, USA; Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK; Swedish Medical Centre, and University of Washington School of Medicine, Seattle, Washington, USA; Monash University, Melbourne, Australia; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service NHS Foundation Trust, University of Manchester, UK; Altoona Center for Clinical Research, Duncansville, Pennsylvania; Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA; Novartis Pharma AG, Basel, Switzerland. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. A. Kavanaugh received research grants or consultation fees from Novartis. I.B. McInnes received research grants, consultation fees, or speaker honoraria from Novartis. P.J. Mease received research grants, consultation fees, or speaker honoraria from Novartis. H. Chinoy received consulting fees/grant support from Novartis. Z. Wang is an employee of Novartis. S. Mpofu is an employee of Novartis and owns Novartis stock. A. Kavanaugh, MD, Professor of Clinical Medicine, Director of Center for Innovative Therapy, University of California–San Diego, School of Medicine; I.B. McInnes, MD, PhD, Professor of Experimental Medicine (Immunology), Muirhead Chair of Medicine and Director of Institute (School of Medicine), Immunology, Infection and Inflammation, University of Glasgow; P.J. Mease, MD, Clinical Professor, University of Washington School of Medicine, Director of the Rheumatology Clinical Research Division of Swedish Medical Center; S. Hall, MBBS, Professor, Director-Emeritus Research, Monash University; H. Chinoy, PhD, Senior Lecturer, Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, University of Manchester; A.J. Kivitz, MD, CPI, President, Altoona Center for Clinical Research; Z. Wang, PhD, Associate Director, Biometrician, Novartis; S. Mpofu, MD, Senior Global Program Medical Director, Novartis. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy, and Immunology, School of Medicine, University of California at San Diego, 9500 Gilman Dr. MC 0943, La Jolla, California 92093-0943, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 9, 2016.
Shephard Mpofu
From the University of California-San Diego, School of Medicine, LaJolla, California, USA; Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK; Swedish Medical Centre, and University of Washington School of Medicine, Seattle, Washington, USA; Monash University, Melbourne, Australia; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service NHS Foundation Trust, University of Manchester, UK; Altoona Center for Clinical Research, Duncansville, Pennsylvania; Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA; Novartis Pharma AG, Basel, Switzerland. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. A. Kavanaugh received research grants or consultation fees from Novartis. I.B. McInnes received research grants, consultation fees, or speaker honoraria from Novartis. P.J. Mease received research grants, consultation fees, or speaker honoraria from Novartis. H. Chinoy received consulting fees/grant support from Novartis. Z. Wang is an employee of Novartis. S. Mpofu is an employee of Novartis and owns Novartis stock. A. Kavanaugh, MD, Professor of Clinical Medicine, Director of Center for Innovative Therapy, University of California–San Diego, School of Medicine; I.B. McInnes, MD, PhD, Professor of Experimental Medicine (Immunology), Muirhead Chair of Medicine and Director of Institute (School of Medicine), Immunology, Infection and Inflammation, University of Glasgow; P.J. Mease, MD, Clinical Professor, University of Washington School of Medicine, Director of the Rheumatology Clinical Research Division of Swedish Medical Center; S. Hall, MBBS, Professor, Director-Emeritus Research, Monash University; H. Chinoy, PhD, Senior Lecturer, Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, University of Manchester; A.J. Kivitz, MD, CPI, President, Altoona Center for Clinical Research; Z. Wang, PhD, Associate Director, Biometrician, Novartis; S. Mpofu, MD, Senior Global Program Medical Director, Novartis. Address correspondence to Dr. A. Kavanaugh, Division of Rheumatology, Allergy, and Immunology, School of Medicine, University of California at San Diego, 9500 Gilman Dr. MC 0943, La Jolla, California 92093-0943, USA. E-mail: akavanaugh@ucsd.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication May 9, 2016.
Article Figures & Data
Additional Files
Data Supplement
Data Supplement
Files in this Data Supplement:
- Data Supplement - Data Supplement
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease, Stephen Hall, Hector Chinoy, Alan J. Kivitz, Zailong Wang, Shephard Mpofu
The Journal of Rheumatology Jun 2016, jrheum.160275; DOI: 10.3899/jrheum.160275
Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease, Stephen Hall, Hector Chinoy, Alan J. Kivitz, Zailong Wang, Shephard Mpofu
The Journal of Rheumatology Jun 2016, jrheum.160275; DOI: 10.3899/jrheum.160275